AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2888477 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 0
Study 31385552 — intervention group
Group type: EXPERIMENTAL
Intervention: VOT manipulation (voice onset time) in two-word sequences with matching and mismatching VOTs.
Number of subjects: 20
Study 31385552 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouse movement trajectories recorded during the task.
Number of subjects: 20
Study 29538179 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron supplementation (ferric carboxymaltose)
Number of subjects: 34
Study 29538179 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron supplementation (ferrous sulfate)
Number of subjects: 34
Study 29538179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 28718081 — intervention group
Group type: EXPERIMENTAL
Intervention: Sage one‐step medium (Origio)
Number of subjects: 33
Study 28718081 — intervention group
Group type: COMPARATOR
Intervention: Continuous Single Culture (CSC) medium (Irvine Scientific)
Number of subjects: 33
Study 26428942 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 courses of cisplatin 100 mg/mq and paclitaxel 175 mg/mq every 21 days (Group A)
Number of subjects: 200
Study 26428942 — intervention group
Group type: COMPARATOR
Intervention: 6 courses of cisplatin 100 mg/mq and paclitaxel 175 mg/mq every 21 days (Group B)
Number of subjects: 200
Study 23229241 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% Arginine-CaCO₃
Number of subjects: 36
Study 23229241 — intervention group
Group type: COMPARATOR
Intervention: 1.23% NaF-gel
Number of subjects: 36
Study 21046229 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 100
Study 21046229 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 100
Study 18261787 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 21
Study 18261787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 17345811 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic hydrophobic foldable intraocular lens with rigid haptics
Number of subjects: 108
Study 17345811 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic hydrophobic foldable intraocular lens with pliable haptics
Number of subjects: 108
Study 17345811 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-piece acrylic hydrophobic IOL with soft acrylic loops
Number of subjects: 108
Study 14662662 — intervention group
Group type: EXPERIMENTAL
Intervention: Artichoke extract (3 capsules)
Number of subjects: 15
Study 14662662 — intervention group
Group type: COMPARATOR
Intervention: Placebo (indistinguishable inert capsules)
Number of subjects: 15
Study 14662662 — intervention group
Group type: EXPERIMENTAL
Intervention: Artichoke extract
Number of subjects: 15
Study 14662662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 11058673 — intervention group
Group type: EXPERIMENTAL
Intervention: Levomethadyl acetate (75 to 115 mg)
Number of subjects: 220
Study 11058673 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (16 to 32 mg)
Number of subjects: 220
Study 11058673 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methadone (60 to 100 mg)
Number of subjects: 220
Study 11058673 — intervention group
Group type: COMPARATOR
Intervention: Low-dose methadone (20 mg)
Number of subjects: 220
Study 8967840 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenergic vegetative neural terminals (VNT) involvement in stroma formation
Number of subjects: 0
Study 8967840 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunocompetent cells involvement
Number of subjects: 0
Study 8967840 — intervention group
Group type: EXPERIMENTAL
Intervention: VNT of the adrenergic part
Number of subjects: 0
Study 8967840 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroma formation in fibroadenoma
Number of subjects: 0
Study 8967840 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomization of stroma formation
Number of subjects: 0
Study 1621669 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg ibuprofen therapy
Number of subjects: 64
Study 1621669 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg acetaminophen therapy
Number of subjects: 64
Study 1621669 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg/kg ibuprofen therapy
Number of subjects: 64
Study 1621669 — intervention group
Group type: COMPARATOR
Intervention: 5 mg/kg ibuprofen therapy
Number of subjects: 64
Study 6487947 — intervention group
Group type: EXPERIMENTAL
Intervention: Small dose of alcohol (0.44 ml.kg‐1)
Number of subjects: 12
Study 6487947 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose of alcohol (0.88 ml.kg‐1)
Number of subjects: 12
Study 6487947 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.0 ml.kg‐1)
Number of subjects: 12
Study 29769080 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic Kidney Transplant Program (HKTP)
Number of subjects: 2
Study 26751765 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated Enterovirus 71 vaccine
Number of subjects: 0
Study 24929936 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (4 sessions of 1 hour per week for 2 weeks)
Number of subjects: 16
Study 24929936 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (1 session of 1 hour per week for 8 weeks)
Number of subjects: 16
Study 23585666 — intervention group
Group type: EXPERIMENTAL
Intervention: L-T3 (liothyronine)
Number of subjects: 13
Study 23585666 — intervention group
Group type: COMPARATOR
Intervention: L-T4 (levothyroxine)
Number of subjects: 13
Study 23585666 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg TRH dose
Number of subjects: 13
Study 20937051 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide IV infusion + oral midodrine 15 mg administered 30 min before furosemide
Number of subjects: 15
Study 20937051 — intervention group
Group type: COMPARATOR
Intervention: Furosemide IV infusion + oral placebo administered 30 min before furosemide
Number of subjects: 15
Study 18384418 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 microg kg(‐1) min(‐1) glyceryl trinitrate (GTN) infusion over 20 min
Number of subjects: 8
Study 18384418 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 8
Study 16730418 — intervention group
Group type: EXPERIMENTAL
Intervention: +ISO (soy protein with 83 mg isoflavones)
Number of subjects: 145
Study 16730418 — intervention group
Group type: COMPARATOR
Intervention: ‐ISO (soy protein with 3 mg isoflavones)
Number of subjects: 145
Study 14680611 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA), 500 mg/day for 5 days
Number of subjects: 30
Study 14680611 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (MIF), 100 mg/day for 5 days
Number of subjects: 30
Study 14680611 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (MIF) + Medroxyprogesterone acetate (MPA), 100 mg/day + 500 mg/day for 5 days
Number of subjects: 30
Study 10875882 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum inhibin A
Number of subjects: 1496
Study 10875882 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum activin A
Number of subjects: 1496
Study 10875882 — intervention group
Group type: COMPARATOR
Intervention: Screening efficacy
Number of subjects: 1496
Study 9537154 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelli-Robson chart
Number of subjects: 39
Study 9537154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cambridge gratings
Number of subjects: 39
Study 9537154 — intervention group
Group type: EXPERIMENTAL
Intervention: Regan chart
Number of subjects: 39
Study 9537154 — intervention group
Group type: EXPERIMENTAL
Intervention: UW chart
Number of subjects: 39
Study 9537154 — intervention group
Group type: EXPERIMENTAL
Intervention: Vistech chart
Number of subjects: 39
Study 9537154 — intervention group
Group type: EXPERIMENTAL
Intervention: All charts
Number of subjects: 39
Study 1440105 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic training in performing case management activities
Number of subjects: 0
Study 1440105 — intervention group
Group type: COMPARATOR
Intervention: Ordinary services provided by the hospital social work department
Number of subjects: 0
Study 2428269 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (10 ml/kg body weight)
Number of subjects: 28
Study 2428269 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.5% oxypolygelatin (10 ml/kg body weight)
Number of subjects: 28
Study 2428269 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0% human albumin (10 ml/kg body weight)
Number of subjects: 28
Study 30282699 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric banding
Number of subjects: 88
Study 30282699 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 88
Study 26332311 — intervention group
Group type: EXPERIMENTAL
Intervention: In-service educational session on IBD health maintenance
Number of subjects: 50
Study 24629060 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport (60 units)
Number of subjects: 60
Study 24629060 — intervention group
Group type: COMPARATOR
Intervention: ISDN (10 mg/ml, 1%)
Number of subjects: 60
Study 22849754 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed Questionnaire (MQ)
Number of subjects: 392
Study 22849754 — intervention group
Group type: COMPARATOR
Intervention: Computer-Assisted Telephone Interview (CATI)
Number of subjects: 392
Study 22849754 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed Questionnaire (MQ) for fathers
Number of subjects: 392
Study 22849754 — intervention group
Group type: COMPARATOR
Intervention: Computer-Assisted Telephone Interview (CATI) for fathers
Number of subjects: 392
Study 20579405 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dairy consumption (500 ml low-fat milk and 150 g low-fat yogurt)
Number of subjects: 35
Study 20579405 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-rich control products (600 ml fruit juice and three fruit biscuits)
Number of subjects: 35
Study 18019902 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless Palm‐based electronic prescribing system
Number of subjects: 0
Study 18019902 — intervention group
Group type: EXPERIMENTAL
Intervention: Workarounds to create acceptable prescribing processes
Number of subjects: 0
Study 16182039 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month oral controlled diet followed by 3-month spontaneous dietary intake
Number of subjects: 90
Study 16182039 — intervention group
Group type: COMPARATOR
Intervention: 3-month spontaneous dietary intake followed by 3-month controlled diet
Number of subjects: 90
Study 16182039 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups during controlled diet
Number of subjects: 90
Study 11205423 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaler
Number of subjects: 504
Study 11205423 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch
Number of subjects: 504
Study 11205423 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum
Number of subjects: 504
Study 11205423 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal Spray
Number of subjects: 504
Study 11205423 — intervention group
Group type: COMPARATOR
Intervention: Control (Preferred Product)
Number of subjects: 504
Study 9032190 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% O2
Number of subjects: 11
Study 9032190 — intervention group
Group type: COMPARATOR
Intervention: Room air (RA)
Number of subjects: 11
Study 7904330 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized progesterone (1,200 mg)
Number of subjects: 18
Study 7904330 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of allopregnanolone and pregnanolone (> or = 95.55 nmol/l)
Number of subjects: 18
Study 7904330 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 18
Study 3030904 — intervention group
Group type: EXPERIMENTAL
Intervention: Bran biscuits (12 biscuits, 1 = 1.3 g fibre)
Number of subjects: 28
Study 3030904 — intervention group
Group type: COMPARATOR
Intervention: Placebo biscuits (12 biscuits, 1 = 0.23 g fibre)
Number of subjects: 28
Study 3030904 — intervention group
Group type: EXPERIMENTAL
Intervention: Bran biscuits
Number of subjects: 28
Study 3030904 — intervention group
Group type: COMPARATOR
Intervention: Placebo biscuits
Number of subjects: 28
Study 30569827 — intervention group
Group type: EXPERIMENTAL
Intervention: Preschool PATHS curriculum
Number of subjects: 5
Study 27336206 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive weight loss intervention (IWL) consisting of 12 weeks of very-low-energy diet (800 kcal/day) + 4 weeks of low-calorie conventional food-based diet (CFD) to promote 15% weight loss.
Number of subjects: 14
Study 27336206 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care nutrition counseling (SCN) consisting of 16 weeks of CFD to promote ≥5% weight loss.
Number of subjects: 14
Study 23039030 — intervention group
Group type: EXPERIMENTAL
Intervention: abacavir/lamivudine + atazanavir/ritonavir
Number of subjects: 515
Study 21142812 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan/HCTZ (50mg/12.5mg daily)
Number of subjects: 29
Study 21142812 — intervention group
Group type: COMPARATOR
Intervention: Losartan (50mg/day)
Number of subjects: 29
Study 18262712 — intervention group
Group type: EXPERIMENTAL
Intervention: PCPT biopsy policy
Number of subjects: 15773
Study 18262712 — intervention group
Group type: COMPARATOR
Intervention: Screening in ERSPC
Number of subjects: 15773
Study 16502143 — intervention group
Group type: EXPERIMENTAL
Intervention: Slick Tracy Home Team Program (intervention group)
Number of subjects: 3623
Study 16502143 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3623
Study 12953850 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (perindopril 4 mg daily, with optional indapamide)
Number of subjects: 6105
Study 12953850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6105
Study 12953850 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (perindopril plus indapamide)
Number of subjects: 6105
Study 12953850 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-drug therapy (perindopril alone)
Number of subjects: 6105
Study 12953850 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 6105
Study 10703679 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline [3%]
Number of subjects: 9
Study 10703679 — intervention group
Group type: COMPARATOR
Intervention: Albumin [20%]
Number of subjects: 9
Study 10703679 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethylstarch (HES) [10%]
Number of subjects: 9
Study 9052518 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose feeding for 10 days
Number of subjects: 6
Study 9052518 — intervention group
Group type: COMPARATOR
Intervention: Dextrose feeding for 10 days
Number of subjects: 6
Study 7870914 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0
Study 7870914 — intervention group
Group type: COMPARATOR
Intervention: Instructions (told caffeine, told no caffeine, not told)
Number of subjects: 0
Study 7870914 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions (told caffeine)
Number of subjects: 0
Study 3039882 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir, 5 mg/kg intravenously every 8 hours
Number of subjects: 45
Study 3039882 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acyclovir)
Number of subjects: 45
Study 3039882 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 45
Study 3039882 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 30083910 — intervention group
Group type: EXPERIMENTAL
Intervention: MyoVision lenses
Number of subjects: 207
Study 30083910 — intervention group
Group type: COMPARATOR
Intervention: Single vision lenses (SVLs)
Number of subjects: 207
Study 27039799 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP-14
Number of subjects: 143
Study 27039799 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP-21
Number of subjects: 143
Study 27039799 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP-14 and R-CHOP-21
Number of subjects: 143
Study 25372219 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity laser therapy (LILT) - 790 nm, 30 mW continuous wave, 0.13 cm2 focal spot, applied energy of 3.6 J, fluence of 27.69 J/cm2
Number of subjects: 80
Study 25372219 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% benzocaine
Number of subjects: 80
Study 25372219 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure
Number of subjects: 80
Study 25372219 — intervention group
Group type: COMPARATOR
Intervention: Light touch
Number of subjects: 80
Study 23457689 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime restriction and basic sleep hygiene
Number of subjects: 45
Study 23457689 — intervention group
Group type: COMPARATOR
Intervention: Basic sleep hygiene only
Number of subjects: 45
Study 19863517 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg PTX‐SR (Apo‐Pentoxifylline, Apotex Inc.) twice daily for 6 months
Number of subjects: 228
Study 19863517 — intervention group
Group type: COMPARATOR
Intervention: Placebo, similar regimen for 6 months
Number of subjects: 228
Study 17666447 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN)
Number of subjects: 315
Study 17666447 — intervention group
Group type: COMPARATOR
Intervention: Etanercept and methotrexate (ETN+MTX)
Number of subjects: 315
Study 20406961 — intervention group
Group type: EXPERIMENTAL
Intervention: Dense breast tissue (pattern IV or V)
Number of subjects: 15658
Study 20406961 — intervention group
Group type: COMPARATOR
Intervention: Nondense breast tissue
Number of subjects: 15658
Study 16537301 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated vaginal microbicide
Number of subjects: 96
Study 12269974 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin 25 mg
Number of subjects: 10
Study 12269974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12269974 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 80 mg
Number of subjects: 10
Study 9727511 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser trabeculoplasty (DLT)
Number of subjects: 46
Study 9727511 — intervention group
Group type: COMPARATOR
Intervention: Argon laser trabeculoplasty (ALT)
Number of subjects: 46
Study 8067273 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy (mean 4106 lx)
Number of subjects: 43
Study 8067273 — intervention group
Group type: COMPARATOR
Intervention: Dim light therapy (mean 96 lx)
Number of subjects: 43
Study 3197677 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotol slow (slow-release carbamazepine), administered twice daily
Number of subjects: 20
Study 3197677 — intervention group
Group type: COMPARATOR
Intervention: Tegretol (conventional carbamazepine), administered three times daily
Number of subjects: 20
Study 29574518 — intervention group
Group type: EXPERIMENTAL
Intervention: Minodronate (MIN) 50 mg once-monthly
Number of subjects: 83
Study 29574518 — intervention group
Group type: COMPARATOR
Intervention: Risedronate (RIS) 75 mg once-monthly
Number of subjects: 83
Study 26781865 — intervention group
Group type: EXPERIMENTAL
Intervention: Announced tenofovir levels
Number of subjects: 268
Study 26781865 — intervention group
Group type: COMPARATOR
Intervention: Unannounced tenofovir levels
Number of subjects: 268
Study 26781865 — intervention group
Group type: EXPERIMENTAL
Intervention: Announced tenofovir levels in Kabwohe
Number of subjects: 268
Study 26781865 — intervention group
Group type: EXPERIMENTAL
Intervention: Announced tenofovir levels in Kampala
Number of subjects: 268
Study 26781865 — intervention group
Group type: EXPERIMENTAL
Intervention: Announced tenofovir levels in Tororo
Number of subjects: 268
Study 26528934 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty (THA) or bipolar prosthesis using MIS transgluteal approach
Number of subjects: 40
Study 26528934 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical approach (control group)
Number of subjects: 40
Study 23247719 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed survey invitation through cancer registry
Number of subjects: 505
Study 20544611 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (TG, n = 32)
Number of subjects: 48
Study 20544611 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 16)
Number of subjects: 48
Study 18356403 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification (ILS) with weight loss of 3-7% body weight
Number of subjects: 0
Study 18356403 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification (ILS) with weight loss of >7% body weight
Number of subjects: 0
Study 18356403 — intervention group
Group type: COMPARATOR
Intervention: Weight loss <3% body weight
Number of subjects: 0
Study 16641239 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory for conjunctions at 8 s delays
Number of subjects: 0
Study 16641239 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory for objects and locations
Number of subjects: 0
Study 16641239 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampus involvement in conjunction working memory
Number of subjects: 0
Study 14623651 — intervention group
Group type: COMPARATOR
Intervention: Conventional magnetic resonance imaging
Number of subjects: 41
Study 14623651 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous contrast-enhanced indirect magnetic resonance arthrography
Number of subjects: 41
Study 14623651 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular contrast-enhanced direct magnetic resonance arthrography
Number of subjects: 41
Study 10783839 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil mouthrinse (Listerine Antiseptic)
Number of subjects: 17
Study 10783839 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline negative control
Number of subjects: 17
Study 8894333 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms)
Number of subjects: 16
Study 8894333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8894333 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 16
Study 2056262 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 53
Study 2056262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 6605082 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 78